Scientists Discover Natural “Off Switch” to Stop Chronic Inflammation

Researchers at University College London have identified a biological pathway involving epoxy-oxylipins that acts as a natural off-switch for inflammation. Published in Nature Communications, a human study utilizing drug-based enzyme inhibition demonstrated that boosting these fat-derived molecules safely limits harmful immune cell expansion without shutting down overall immunity.

Inflammation acts as the body’s frontline defense against tissue damage and infection. While acute inflammation is necessary for healing, chronic inflammation serves as a primary driver for major global health threats, including cardiovascular disease, type 2 diabetes, arthritis, and neurodegenerative disorders. For decades, clinical research has focused heavily on how immune responses begin, while the precise signaling molecules that actively terminate these reactions remained poorly understood. Now, investigators have mapped a previously underappreciated pathway that resolves inflammatory responses before tissue damage escalates.

Mapping the Body’s Natural Lipid Brakes

The study centers on a group of naturally produced fat molecules known as epoxy-oxylipins. These signaling molecules are synthesized through cytochrome P450 enzymes acting on fatty acids. Earlier animal models hinted that these compounds possessed pain-relieving and anti-inflammatory properties, but their precise mechanism of action and human relevance had never been mapped in clinical trials. To investigate, researchers at University College London induced a controlled, temporary inflammatory response in healthy volunteers by administering small injections of ultraviolet-killed E. coli bacteria into the forearm. This method generated localized redness, heat, swelling, and pain mirroring a standard immune reaction to injury.

Participants were divided into prophylactic and therapeutic cohorts to test the intervention under different clinical scenarios. The therapeutic arm assessed intervention after symptoms fully appeared, while the prophylactic arm evaluated whether boosting the molecules early could limit adverse immune shifts. Subjects received a pharmacological agent named GSK2256294. This specific compound inhibits soluble epoxide hydrolase (sEH), an enzyme that normally degrades epoxy-oxylipins. By blocking sEH, the treatment successfully elevated systemic and local concentrations of these protective lipid molecules, particularly a compound designated as 12,13-EpOME.

In Plain English: The Clinical Takeaway

• Targeted Resolution: Unlike broad immunosuppressive drugs that can leave patients vulnerable to secondary infections, this mechanism selectively calms harmful immune escalation while preserving baseline immune defense.
• Cellular Impact: The intervention significantly reduced intermediate monocytes—specialized immune cells heavily implicated in chronic inflammatory diseases and tissue degradation.
• Pain Resolution: Clinical monitoring showed that boosting these fat molecules helped local pain resolve much more quickly in human test subjects.

The molecular investigation revealed that 12,13-EpOME operates by interfering with p38 MAPK, a critical cellular signaling protein that drives the transformation of monocytes into highly inflammatory states. When researchers blocked this pathway, inflammatory monocyte counts dropped precipitously. Dr. Olivia Bracken from the UCL Department of Ageing, Rheumatology and Regenerative Medicine explained the clinical significance of these findings, stating, “Our findings reveal a natural pathway that limits harmful immune cell expansion and helps calm inflammation more quickly. Targeting this mechanism could lead to safer treatments that restore immune balance without suppressing overall immunity.”

Translational Potential and Therapeutic Repurposing

The implications of this trial extend directly to autoimmune and chronic inflammatory conditions where traditional therapeutics often carry severe adverse side effects. Because GSK2256294 is already recognized as a drug suitable for human use, the compound holds immediate potential for clinical repurposing. Professor Derek Gilroy, corresponding author from the UCL Division of Medicine, noted the clinical horizon for these findings: “This is the first study to map epoxy-oxylipin activity in humans during inflammation. By boosting these protective fat molecules, we could design safer treatments for diseases driven by chronic inflammatory conditions, an area currently lacking targeted resolution therapies.”

Clinical Trial Parameters of sEH Inhibition Study

Parameter	Prophylactic Arm	Therapeutic Arm
Total Volunteers (N)	24 (12 treated, 12 placebo)	24 (12 treated, 12 placebo)
Timing of Drug Administration	2 hours prior to inflammation	4 hours after inflammation onset
Primary Biological Target	Soluble epoxide hydrolase (sEH)	Soluble epoxide hydrolase (sEH)
Key Biomarker Modulated	12,13-EpOME / Intermediate Monocytes	12,13-EpOME / Intermediate Monocytes

While the drug successfully reduced intermediate monocytes and accelerated pain recovery, it did not significantly alter outward physical signs like localized swelling or surface redness. This clinical nuance highlights that the pathway specifically targets internal immune escalation and tissue-damaging cellular trafficking rather than superficial vasodilation.

Contraindications & When to Consult a Doctor

Ultimately, mapping human epoxy-oxylipin activity provides a robust framework for future drug development.

References

• Nature Communications: Human clinical evaluation of soluble epoxide hydrolase inhibition during acute inflammation.
• University College London Division of Medicine: Research publications on epoxy-oxylipins and cytochrome P450 pathways.
• ScienceDaily: Investigative summaries on the discovery of natural inflammation off-switches.

Disclaimer: This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.